Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HYPR NYSE:NSPR NASDAQ:NVNO OTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHYPRHyperfine$1.23+3.8%$0.82$0.53▼$1.90$95.34M1.061.50 million shs269,073 shsNSPRInspireMD$2.48-7.1%$2.43$1.99▼$3.80$75.98M0.6103,662 shs79,381 shsNVNOenVVeno Medical$4.89+0.9%$4.28$2.03▼$5.81$85.68M1.01107,201 shs34,236 shsVASOVaso$0.12+5.9%$0.13$0.11▼$0.32$21.77M1.5777,932 shs79,551 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHYPRHyperfine+14.56%+7.27%+49.56%+75.33%+2.61%NSPRInspireMD-0.74%+9.43%+18.40%+5.95%-10.10%NVNOenVVeno Medical-0.62%-6.38%+18.34%+38.68%-6.20%VASOVaso-4.88%-4.33%-6.70%-7.87%-52.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHYPRHyperfine0.9876 of 5 stars1.32.00.00.02.22.50.6NSPRInspireMD3.6279 of 5 stars3.53.00.00.03.94.20.6NVNOenVVeno Medical0.3611 of 5 stars0.02.00.00.01.50.80.6VASOVasoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHYPRHyperfine 2.67Moderate Buy$1.06-13.47% DownsideNSPRInspireMD 3.00Buy$4.5081.45% UpsideNVNOenVVeno Medical 0.00N/AN/AN/AVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VASO, HYPR, NSPR, and NVNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.685/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHYPRHyperfine$12.89M7.40N/AN/A$0.67 per share1.83NSPRInspireMD$7.03M10.81N/AN/A$1.83 per share1.36NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/AVASOVaso$86.77M0.25$0.01 per share12.16$0.16 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/13/2025 (Estimated)NSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ANVNOenVVeno Medical-$21.82M-$1.20N/AN/AN/AN/A-57.35%-53.49%N/AVASOVaso$950KN/A0.00∞N/A1.20%3.93%1.37%8/12/2025 (Estimated)Latest VASO, HYPR, NSPR, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025HYPRHyperfine-$0.12N/AN/AN/A$3.00 millionN/A7/31/2025Q2 2025NVNOenVVeno Medical-$0.28-$0.33-$0.05-$0.33N/AN/A5/15/2025Q1 2025VASOVasoN/A-$0.01N/A-$0.01N/A$19.46 million5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHYPRHyperfineN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHYPRHyperfineN/A6.075.48NSPRInspireMDN/A6.396.05NVNOenVVeno MedicalN/A11.8111.81VASOVasoN/A1.521.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHYPRHyperfine15.03%NSPRInspireMD44.78%NVNOenVVeno Medical34.71%VASOVasoN/AInsider OwnershipCompanyInsider OwnershipHYPRHyperfine30.98%NSPRInspireMD34.06%NVNOenVVeno Medical16.00%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHYPRHyperfine19077.83 million53.72 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableNVNOenVVeno Medical3017.54 million14.73 millionOptionableVASOVaso260175.74 million97.54 millionNot OptionableVASO, HYPR, NSPR, and NVNO HeadlinesRecent News About These CompaniesGreece stuns USA to reach women’s water polo World Championship finalJuly 23, 2025 | neoskosmos.comNLevel of physical activity tied to less pain, blood viscosity in SCD: StudyJune 26, 2025 | sicklecellanemianews.comSCorn in a Cup (Elote en Vaso)June 7, 2025 | msn.comOral inhibitor rilzabrutinib granted FDA orphan drug status for SCDJune 5, 2025 | sicklecellanemianews.comSUS FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell diseaseJune 5, 2025 | pharmabiz.comPSanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell diseaseJune 4, 2025 | medicaldialogues.inMPress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseJune 3, 2025 | taiwannews.com.twTSickle cell disease and knee joint pain: Why steriods aren’t always the best optionMay 30, 2025 | punchng.comPVaso Corporation Registered ShsMay 20, 2025 | markets.businessinsider.comVaso Stock Slips Post Q1 Earnings Despite Record Revenue GrowthMay 20, 2025 | zacks.comVaso Corporation Announces Financial Results for First Quarter of 2025May 15, 2025 | globenewswire.comNew tapas and wine bar to open in Nottingham from the team behind MesaMay 6, 2025 | msn.comHe compared him to Justin Bieber, but he got what he deserved in the ringApril 24, 2025 | msn.comThe Zacks Analyst Blog Highlights Apple, Philip Morris International, Sony and VasoApril 21, 2025 | uk.finance.yahoo.comC-Reactive Protein Increases During Menstrual Cycle in Females With Sickle Cell DiseaseApril 18, 2025 | rheumatologyadvisor.comRTop Analyst Reports for Apple, Philip Morris & SonyApril 17, 2025 | finance.yahoo.comShake up your Monday: VASO hosts an electrifying cocktail showdown with top bartendersApril 17, 2025 | myfox28columbus.comMInflammation during menstrual cycle may trigger VOEs: StudyApril 15, 2025 | sicklecellanemianews.comSDangerous 'crises' in sickle cell disease may be amplified by menstrual cycleApril 14, 2025 | msn.comVASO Stock Rises Post Q4 Revenue Growth and Solid Segment GainsApril 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVASO, HYPR, NSPR, and NVNO Company DescriptionsHyperfine NASDAQ:HYPR$1.23 +0.05 (+3.81%) As of 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.InspireMD NYSE:NSPR$2.48 -0.19 (-7.12%) As of 02:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.enVVeno Medical NASDAQ:NVNO$4.88 +0.05 (+0.93%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Vaso OTCMKTS:VASO$0.12 +0.01 (+5.90%) As of 11:00 AM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? META Gets Huge Upgrades: How High Analysts Think Shares Could Go Novo Nordisk Stock Sinks—But Is a Bottom Finally In? Why Citigroup Analysts See Double-Digit Upside in Coinbase Stock A New AI Tailwind Could Come to Boost Taiwan Semiconductor Stock How 2 Deals in 48 Hours Changed Everything for Joby Aviation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
